Related Experiment Video
Updated: May 30, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Mycoplasma hyopneumoniae type I signal peptidase: expression and evaluation of its diagnostic potential
Lucas Moitinho-Silva1, Bianca L Heineck, Luciano A Reolon
1Laboratório de Genômica Estrutural e Funcional, Centro de Biotecnologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Abstract:
Type I signal peptidase (SPase I) is a membrane-anchored protease of the general secretory pathway, which is encoded by the sipS gene in Mycoplasma hyopneumoniae, the etiological agent of porcine enzootic pneumonia (PEP). In this study, the expression of the M. hyopneumoniae SPase I (MhSPase I) was analyzed in virulent and avirulent strains, and the recombinant protein (rMhSPase I), expressed in Escherichia coli, was evaluated regarding its potential as an immunodiagnostic antigen. It was demonstrated that the sipS coding DNA sequence (CDS) is most likely part of an operon, being co-transcribed along with four other CDSs. Quantitative reverse transcriptase PCR and immunoblot assays showed that MhSPase I is expressed by all three strains analyzed, with no transcriptional difference, but with evidence of a higher protein level in a pathogenic strain (7422), in comparison to another pathogenic (7448) and a non-pathogenic (J) strain. rMhSPase I was strongly immunogenic for mice, and the MhSPase I antigenicity was confirmed. Polyclonal serum anti-rMhSPase I presented no detectable cross-reaction with Mycoplasma flocculare and Mycoplasma hyorhinis. Moreover, phylogenetic analysis demonstrated a low conservation between MhSPase I and orthologous proteins from other porcine respiratory disease complex-related bacteria, Firmicutes and other Mycoplasma species. The potential of an rMhSPase I-based ELISA for PEP immunodiagnosis was demonstrated. Overall, we investigated the expression of sipS and the encoded MhSPase I in three M. hyopneumoniae strains and showed that this protein is a good antigen for use in PEP serodiagnosis and possibly vaccination, as well as a potential target for antibiotic development.
Insights
Type I signal peptidase (SPase I) from Mycoplasma hyopneumoniae is expressed in different strains and shows potential as an antigen for diagnosing porcine enzootic pneumonia (PEP). This protein could also be a target for new antibiotics.
Area of Science:
- Microbiology
- Molecular Biology
- Immunology
Background:
- Mycoplasma hyopneumoniae causes porcine enzootic pneumonia (PEP).
- Type I signal peptidase (SPase I), encoded by sipS, is crucial for the general secretory pathway in bacteria.
- Understanding SPase I expression and antigenicity is key for diagnostics and therapeutics.
Purpose of the Study:
- To analyze the expression of M. hyopneumoniae SPase I (MhSPase I) in different strains.
- To evaluate the potential of recombinant MhSPase I (rMhSPase I) as an immunodiagnostic antigen for PEP.
- To explore MhSPase I as a potential target for antibiotic development.
Main Methods:
- Quantitative reverse transcriptase PCR (qRT-PCR) to analyze sipS gene expression.
- Immunoblot assays to detect MhSPase I protein levels.
- Expression of recombinant rMhSPase I in Escherichia coli.
- Immunization of mice with rMhSPase I and antibody characterization.
- Phylogenetic analysis of MhSPase I.
Main Results:
- The sipS gene is likely part of an operon, co-transcribed with other genes.
- MhSPase I is expressed at the protein level in all analyzed M. hyopneumoniae strains, with higher levels in a pathogenic strain.
- Recombinant MhSPase I is immunogenic and specific, showing no cross-reactivity with other Mycoplasma species.
- Phylogenetic analysis reveals low conservation with related bacterial proteins.
- An ELISA based on rMhSPase I shows potential for PEP immunodiagnosis.
Conclusions:
- MhSPase I is expressed in M. hyopneumoniae, with variations in protein levels between strains.
- rMhSPase I is a promising antigen for serodiagnosis of PEP.
- MhSPase I is a potential candidate for vaccine development and a target for novel antibiotics.
Related Concept Videos
Atypical Pneumonia
Pneumonia III: Complications and Assessment